#pharmacy-benefit-managers

#pharmacy-benefit-managers

Increased inhaler prices after policy changes by UnitedHealthcare's PBM allegedly contributed to a young man's death from asthma.

Pharmacy benefit managers are driving small pharmacies out of business, severely impacting rural healthcare access.

Trump's comments about pharmacy benefit managers led to significant stock declines for major healthcare companies.

The FTC is taking action against major pharmacy benefit managers for inflating insulin prices and harming consumers.

The FTC is suing major pharmacy benefit managers for unfair practices affecting insulin prices and patient access.

Pharmacy Benefit Managers are fighting the FTC's lawsuit to maintain their practices amid accusations of anticompetitive behavior regarding insulin.

The FTC is suing three PBMs for allegedly inflating insulin prices, impacting many Americans reliant on the drug.

Federal regulators accuse major pharmacy benefit managers of driving up insulin costs and limiting access to cheaper versions, impacting millions of diabetes patients.

OptumRx is accused of massively inflating the prices of life-saving medications, causing significant financial burdens for patients.

New bipartisan legislation seeks to prevent health insurers from owning pharmacies, targeting the monopolistic power of pharmacy benefit managers.

If enacted, this legislation could disrupt the current healthcare market dominated by a few conglomerates. The effort highlights ongoing concerns about drug pricing and transparency.

FTC report reveals significant price hikes by PBMs on critical medications, calling for investigations into practices inflating drug costs and harming healthcare accessibility.

A former J&J advocate is suing her employer over high drug costs due to its contract with a pharmacy benefit manager.

The lawsuit shines light on the financial impacts of PBM relationships on employees.

New law removes 'gag clause' for pharmacists, enhancing transparency on medication pricing and accessibility.

Congress' funding bill introduces key healthcare reforms targeting pharmacy benefit managers, telehealth access, and payment increases for hospitals and physicians.

Pharmacy benefit managers (PBMs) are largely unregulated and significantly impact the access and cost of medications for patients.

The opioid crisis highlights corporate corruption and the failures of a for-profit healthcare system that prioritizes profits over patient safety.

Congress is advancing bills to dismantle major insurance monopolies following Brian Thompson's murder, reflecting significant public outrage towards the healthcare system.

The Patients Before Monopolies Act seeks to divest PBMs from pharmacy ownership to prevent conflicts of interest and reduce drug costs.

The FTC is legally challenging major pharmacy benefit managers for inflating insulin prices and blocking patient access to cheaper drugs.

Independent pharmacists face existential threats from pharmacy benefit managers that steer patients away and impose high fees, jeopardizing community healthcare.

Pharmacy deserts are emerging in the U.S. as independent pharmacies close due to the practices of pharmacy benefit managers.

Congress must act to regulate pharmacy benefit managers (PBMs) to protect patient access to medications and support independent pharmacies.

Employers lack understanding of what PBMs do with drug rebates, highlighting a need for greater transparency.

The FTC alleges that pharmacy benefit managers inflate insulin prices through rebate programs, harming patients financially.

Bipartisan scrutiny highlights the complexities of prescription drug pricing, implicating pharmacy benefit managers, Big Pharma, distributors, and hospitals in driving costs up.

Pharmacy benefit managers often go unnoticed but significantly contribute to the rising costs of prescription drugs for millions of Americans.

Hospitals and pharmacy benefit managers avoided major federal reforms in the recent congressional spending deal.

The lack of big policy changes could potentially lead to higher health costs for patients.

Wells Fargo accused of mismanaging employee health plan, overcharging for drugs.

Prescription drug costs in California surged 39% in five years, prompting calls for regulatory action to protect patients.

California is seeking to regulate pharmacy benefit managers to control rising prescription drug costs, driven by intermediaries' profit-driven practices.